Sapient Bioanalytics, LLC

Based in California, US, and founded in 2020, Sapient Bioanalytics, LLC, aka Sapient operates as a biomarker discovery lab that identifies small molecule biomarkers (a measurable indicator of some biological state or condition) and derives actionable insights to help client companies accelerate their drug development programs. In July 2022, the firm raised USD 9. 2 million in grant funding from returning investor Bill & Melinda Gates Foundation, and as of August 2022, the company is being led by its founder and Chief Executive Officer, Mohit Jain. Tao Long, Sean Ramsey, Saumya Tiwari, and Jeramie Watrous are the co-founders of the firm.

Sapient Bioanalytics, LLC engages in the discovery of small molecule biomarkers, and the development of targeted, quantitative CLIA (Chemiluminescence Immunoassay) assays to help pharmaceutical and biotechnology companies identify and optimize the best drug candidates for clinical development. The company’s biomarker discovery platform utilizes rapid liquid chromatography-mass spectrometry (rLC-MS), biocomputational learning technologies, and a proprietary human chemical database for its large-scale, small molecule biomarker profiling process. Sapient Bioanalytics, LLC intends to utilize the July 2022 funding to fuel its studies to identify more biomarkers that will help disease prevention as well as disease-treatment interventions.